Please assess the completion status of the following clinical trial:

Trial Title: Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CC resistant PCOS~* Infertile~* Females~* Age 18-38~Exclusion Criteria:~* Hyperprolactinaemia~* Cushing syndrome~* Adult onset adrenal hyperplasia~* Age \>38~* Other infertility factors in the couple than PCOS: male factor,tubal factor,edometriosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: f

Study Arms:
- Clomiphene Citrate plus HP uFSH (Type: EXPERIMENTAL): Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
- Step-up HP uFSH (Type: ACTIVE_COMPARATOR): HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter

Based on this trial design, predict the completion outcome and termination type (if applicable).